Cardiac drug use in pregnancy: Safety, effectiveness and obstetric implications

Expert Review of Cardiovascular Therapy

Volumn 7, Issue 12, 2009, Pages 1569-1580

  Newstead Angel, Jill ^b   Gibson, Paul S ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Acquired heart disease; Antiarrhythmic; Anticoagulant; Antihypertensive; Arrhythmia; Cardiomyopathy; Congenital heart disease

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE; ALISKIREN; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDRALAZINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LABETALOL; LOOP DIURETIC AGENT; METHYLDOPA; METOPROLOL; NIFEDIPINE; NITRATE; PROCAINAMIDE; SOTALOL; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VERAPAMIL; WARFARIN;

BRADYCARDIA; BRONCHOSPASM; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; DEPRESSION; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DYSPNEA; FATIGUE; HEART ARRHYTHMIA; HEART INFARCTION; HEART VENTRICLE TACHYCARDIA; HEMOLYSIS; HUMAN; HYPOTENSION; INTRAUTERINE GROWTH RETARDATION; LOW DRUG DOSE; LUNG EDEMA; LUPUS ERYTHEMATOSUS; MATERNAL HYPERTENSION; MATERNAL MORTALITY; NONHUMAN; PREGNANCY; PREGNANCY COMPLICATION; REVIEW; SIDE EFFECT; SUPRAVENTRICULAR TACHYCARDIA; TACHYCARDIA; VENOUS THROMBOEMBOLISM;

ADRENERGIC BETA-ANTAGONISTS; ANTICOAGULANTS; CARDIOVASCULAR AGENTS; DIURETICS; FEMALE; HUMANS; PLATELET AGGREGATION INHIBITORS; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR;

EID: 73349116886     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.09.152     Document Type: Review

References (85)

1. Steer PJ. Pregnancy and contraception. In: Adult Congenital Heart Disease. A Practical Guide. Gatzoulis M, Swan L, Therrien J, Pantley G (Eds). Blackwell, London, UK, 16-36 (2005).
2. Lewis G (Ed.). The Confidential Enquiry into Maternal and Child Health (CEMACH). Saving Mothers' Lives: reviewing maternal deaths to make motherhood safer - 2003-2005. In: The Seventh Report on Confidential Enquiries into Maternal Deaths in the United Kingdom. CEMACH, London, UK (2007).
3. Siu SC, Colman JM. Heart disease and pregnancy. Heart 85, 710-715 (2001).
4. Gelson E, Gatzoulis MA, Steer P, Johnson MR. Heart disease - why is maternal mortality increasing? BJOG 116(5), 609-611 (2009).
5. Yeomans ER, Gilstrap LC. Physiologic changes in pregnancy and their impact on critical care. Crit. Care Med. 33(Suppl.), S256-S258 (2005).
6. Elkayam U, Gleicher N. Hemodynamics and cardiac function during normal pregnancy and the puerperium. In: Cardiac Problems in Pregnancy. Elkayam U, Gleicher N, Wiley-Liss (Eds). John Wiley and Sons, USA (1998).
7. Van Oppen ACA, Van Der Tweel I, Alsbach GP, Heethaar RM, Bruinse HW. A longitudinal study of maternal hemodynamics during normal pregnancy. Obstet. Gynecol. 88, 40-46 (1996).
8. Tsiaras SV, Poppas A. Normal Changes in Cardiovascular Hemodynamics in Pregnancy, in Medical Care of the Pregnant Patient. American College of Physicians. Rosene-Montella K, Keely EJ, Lee RV, Barbour LA (Eds). ACP Press, PA, USA, 311-318 (2007).
9. Clark SL, Belfort MA, Dildy GA, Herbst MA, Meyers JA, Hankins GD. Maternal death in the 21st Century: causes, prevention, and relationship to cesarean delivery. Am. J. Obstet. Gynecol. 199, 36, E1-E5 (2008).
10. Elkayam U, Akhter MW, Singh H et al. Pregnancy-associated cardiomyopathy: clinical characteristics and a comparison between early and late presentation. Circulation 111, 2050-2055 (2005).
11. Siu SC, Sermer M, Colman JM et al. Prospective multicentre study of pregnancy outcomes in women with heart disease. Circulation 104, 515-521 (2001). • Landmark study identifying multivariate predictors or maternal and fetal complications in pregnancies complicated by maternal cardiac disease, and outlining a prediction rule.
12. Khairy P, Ouyang DW, Fernandes SM. Pregnancy outcomes in women with congenital heart disease. Circulation 113, 517-524 (2006).
13. Weiss BA, Zemp L, Seifert B, Hess OM. Outcome of pulmonary vascular disease in pregnancy. J. Am. Coll. Cardiol. 31, 1650-1657 (1998).
14. Elkayam U, Tummala PP, Rao K et al. Maternal and fetal outcomes of subsequent pregnancies in women with peripartum cardiomyopathy. N. Engl. J. Med. 344, 1567-1571 (2001).
15. Thorne SA. Pregnancy in heart disease. Heart 90, 450-456 (2004).
16. Drenthen W, Pieper PG, Roos-Hesselink JW et al. Outcome of pregnancy in women with congenital heart disease: a literature review. J. Am. Coll. Cardiol. 49(24), 2303-2311 (2007).
17. Whitehead SJ, Berg CJ, Chang J. Pregnancyrelated mortality due to cardiomyopathy: United States, 1991-1997. Obstet. Gynecol. 102, 1326-1331 (2003).
18. Tawam M, Levine J, Mendelson M, Goldberger J, Dyer A, Kadish A. Effect of pregnancy on paroxysmal supraventricular tachycardia. Am. J. Cardiol. 72(11), 838-840 (1993).
19. Lee SH, Chen SA, Wu TJ et al. Effects of pregnancy on first onset and symptoms of paroxysmal supraventricular tachycardia. Am. J. Cardiol. 76(10), 675-678 (1995).
20. Widerhorn J, Wilderhorn A, Rahimtoola S, Elkayam U. WPW syndrome during pregnancy: increased incidence of supraventricular arrhythmias. Am. Heart J. 123, 769-798 (1992).
21. Brodsky M, Doria R, Allen B, Sato D, Thomas G, Sada M. New onset ventricular tachycardia during pregnancy. Am. Heart J. 123, 933-941 (1992).
22. Dawes M, Chowienczyk PJ. Pharmacokinetics in pregnancy. Best Pract. Res. Clin. Obstet. Gynaecol. 15(6), 819-826 (2001). • Good review of how the physiological changes of pregnancy affect medication use in pregnancy.
23. Steinburg I, Moriguchi Mitani G, Harrison EC, Elkayam U. Pharmacokinetics of drugs in pregnancy and lactation. In: Cardiac Problems in Pregnancy (3rd Edition). Elkayam U, Gleicher N (Eds). Wiley-Liss, USA, 341-356 (1998).
24. Doering PL, Boothby LA, Cheok M. Review of pregnancy labeling of prescription drugs: is the current system adequate to inform risks? Am. J. Obstet. Gynecol. 187, 333-339 (2002).
25. Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk (8th Edition). Lippincott, Williams and Wilkins, PA, USA (2007)
26. Hale TW. Medications and Mothers' Milk: A Manual of Lactation Pharmacology (11th Edition). Pharmasoft Medical Publications, TX, USA (2004). • Excellent resource for information on medication use during lactation.
27. Koren G, Pastuszak A, Ito S. Drugs in pregnancy. N. Engl. J. Med. 338(16), 1128-1137 (1998).
28. Little BB, Gilstrap LC. Cardiovascular drugs during pregnancy. Clin. Obstet. Gynecol. 32(1), 13-20 (1989).
29. Magee LA, Ornstein MP, von Dadelszen P. Clinical review - management of hypertension in pregnancy. BMJ 318, 1332-1336 (1999).
30. Magee LA. Antihypertensives. Best Pract. Res. Clin. Obstet. Gynaecol. 15(6), 827-845 (2001). • Excellent review of hypertensive disorders of pregnancy, including treatment and medications.
31. Butters L, Kennedy S, Rubin PC. Atenolol in essential hypertension during pregnancy. BMJ 301, 587-589 (1990).
32. Hurst AK, Hoffman K, Frishman WH, Elkayam U. The use of b-adrenergic blocking agents in pregnancy and lactation. In: Cardiac Problems in Pregnancy (3rd Edition). Elkayam U, Gleicher N (Eds). Wiley-Liss, USA, 341-356 (1998).
33. von Dadelszen P, Ornstein MP, Bull SB, Logan AG, Koren G, Magee LA. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis. Lancet 355, 87-92 (2000).
34. Magee LA, Helewa M. Diagnosis, evaluation, and management of hypertensive disorders of pregnancy. J. Obstet. Gynaecol. Can. 30(3), S1-S48 (2008).
35. Magee LA, Schick B, Donnenfeld AE et al. The safety of calcium channel blockers in human pregnancy: a prospective, multicentre cohort study. Am. J. Obstet. Gynecol. 174(3), 823-828 (1996).
36. Brown MA, Buddle ML, Farrell T et al. Efficacy and safety of nifedipine tablets for the acute treatment of severe hypertension in pregnancy. Am. J. Obstet. Gynecol. 187(4), 1046-1050 (2002).
37. Papatsonis DN. Lok CA. Bos JM et al. Calcium channel blockers in the management of preterm labor and hypertension in pregnancy. Eur. J. Obstet. Gynaecol. Repro. Bio. 97(2), 122-140 (2001).
38. Ahn HK. Nava-Ocampo AA, Han JY et al. Exposure to amlodipine in the first trimester of pregnancy and during breastfeeding. Hypertens. Preg. 26(2), 179-187 (2007).
39. O'Hare MF, Murnaghan GA, Russell CJ et al. Sotalol as a hypotensive agent in pregnancy. BJOG 87, 814-820 (1980).
40. Wagner X, Jouglard J, Moulin M et al. Co-administration of flecainide acetate and sotalol during pregnancy: lack of teratogenic effects, passage across the placenta, and excretion in human breast milk. Am. Heart J. 119, 700-702 (1990).
41. Joglar JA, Page RL. Treatment of cardiac arrythmias during pregnancy: safety considerations. Drug Safety 20(1), 85-94 (1999).
42. James PR. Cardiovascular disease. Best Pract. Res. Clin. Obstet. Gynaecol. 15(6), 903-911 (2001). • Good overview of the cardiovascular diseases that can be seen in pregnancy along with treatment options.
43. Kanai M, Shimizu M, Shiozawa T, Ashida T, Sawaki S, Fujii S. Use of intravenous adenosine triphosphate (ATP) to terminate supraventricular tachycardia in a pregnant woman with Wolff-Parkinson-White syndrome. J. Obstet. Gynaecol. Res. 22(1), 95-99 (1996).
44. Elkayam U, Goodwin TM. Adenosine therapy for supraventricular tachycardia during pregnancy. Am. J. Cardiol. 75(7), 521-523 (1995).
45. Groves TD. Corenblum B. Spironolactone therapy during human pregnancy. Am. J. Obstet. Gynecol. 172(5), 1655-1656 (1995).
46. Shotan A, Widerhorn J, Hurst A, Elkayam U. Risks of angiotensin- converting enzyme inhibition during pregnancy: experimental and clinical evidence, potential mechanisms, and recommendations for use. Am. J. Med. 96, 451-456 (1994).
47. Cooper W, Hernandez-Diaz S et al. Major congenital malformations after first trimester exposure to ACE inhibitors. N. Engl. J. Med. 354(23), 2443-2451 (2006).
48. Cheng JWM. Aliskiren: renin inhibitor for hypertension management. Clin. Ther. 30(1), 31-47 (2008).
49. Sibai B. Treatment of hypertension in pregnant women. N. Engl. J. Med. 335(4), 257-265 (1996).
50. Ounsted MK, Moar VA, Good FJ, Redman CW. Hypertension during pregnancy with and without specific treatment; the development of the children at the age of four years. Br. J. Obstet. Gynaecol. 87(1), 19-24 (1980).
51. James PR, Nelson-Piercy C. Management of hypertension before, during and after pregnancy. Heart 90, 1499-1504 (2004).
52. Rosenfeld J, Bott-Kanner G, Boner G et al. treatment of hypertension during pregnancy with hydralazine monotherapy or with combined therapy with hydralazine and pindolol. Eur. J. Obstet. Gynecol. Reprod. Biol. 22, 197-204 (1986).
53. Murali S, Baldisseri MR. Peripartum cardiomyopathy. Crit. Care Med. 33(Suppl.), S340-S346 (2005).
54. Brugts JJ, Yetgin T, Hoeks SE et al. The benefit of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomized controlled trials. BMJ 30(338), B2376 (2009).
55. Kazmin A, Garcia-Bournissen F, Koren G. Risk of statin use during pregnancy; a systematic review. J. Obstet. Gynaecol. Can. 29(11), 906-908 (2007).
56. Taguchi N, Rubin ET, Hosokawa A et al. Prenatal exposure to HMG-CoA reductase inhibitors: effects on fetal and neonatal outcomes. Reprod. Toxicol. 26(2), 175-177 (2008).
57. Iqbal K, Dar MA. Treatment of pregnancy induced hypertension with IV nitroglycerin. A randomized double blind placebo controlled study. J. Am. Coll. Cardiol. 45(3 Suppl.), A375 (2005).
58. Schleussner E, Möller A, Gross W et al. Maternal and fetal side effects of tocolysis using transdermal nitroglycerin or IV fenoterol combined with magnesium sulfate. Eur. J. Obstet. Gynecol. Reprod. Biol. 106(1), 14-19 (2003).
59. Shoemaker CT, Meyers M. Sodium nitroprusside for control of severe hypertensive disease of pregnancy: a case report and discussion of potential toxicity. Am. J. Obstet. Gynecol. 149(2), 171-173 (1984).
60. Weitz JI. Low molecular weight heparins. N. Engl. J. Med. 337(10), 688-698 (1997).
61. Gibson P, Rosene-Montella. Anticoagulants. Best Pract. Res. Clin. Obstet. Gynaecol. 15(6), 847-861 (2001).
62. Le Templier G, Rodger MA. Heparininduced osteoporosis and pregnancy. Curr. Opin. Pulm. Med. 14, 403-407 (2008).
63. Horlocker TT, Wedel DJ, Benzon H et al. Regional anesthesia in the anticoagulated patient; defining the risks (the second ASRA consensus conference on neuraxial anesthesia and anticoagulation). Reg. Anesth. Pain Med. 28(3), 172-197 (2003).
64. Spinler S. New concepts in heparininduced thrombocytopenia: diagnosis and management. J. Thromb. Thrombolysis 21(1), 17-21 (2006).
65. Young SK, Al-Mondhiry HA, Vaida SJ, Ambrose A, Botti JJ. Succesful use of argatroban during the third trimester of pregnancy: case report and review of the literature. Pharmacotherapy 28(12), 1531-1536 (2008).
66. Gibson P, Powrie R. Anticoagulants and pregnancy: when are they safe? Cleve. Clin. J. Med. 76(2), 113-126 (2009). • Summary of agents and indications for anticoagulation during pregnancy, including a summary of data on newer anticoagulants.
67. Duhl AJ, Paidas MJ, Ural SH et al. Antithrombotic therapy and pregnancy: consensus report and recommendations for prevention and treatment of venous thromboembolism and adverse pregnancy outcomes. Am. J. Obstet. Gynecol. 197(457), E1-E457,.E21 (2007).
68. Mazzolai L, Hohlfeld P, Spertini F, Hayoz D, Schapira M, Duchosal MA. Fondaparinux is a safe alternative in case of heparin intolerance during pregnancy. Blood 108, 1569-1570 (2006).
69. Bates SM, Greer IA, Pabinger I et al. Venous thromboembolism, thrombophilia, antithrombotic therapy and pregnancy. Chest 133, S844-S886 (2008).
70. Lindoff-Last E, Kreutzenbeck HJ, Magani HN. Treatment of 51 pregnancies with danaparoid because of heparin intolerance. Thromb. Haemost. 93, 63-69 (2005).
71. Chan WS, Anand S, Ginsberg JS. Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Arch. Intern. Med. 160, 191-196 (2000).
72. Czeizel AE, Rockenbauer M, Mosonyi A. A population based case control teratologic study of acetylsalicylic acid treatments during pregnancy. Pharmacoepidemiol. Drug Saf. 9(3), 193-205 (2000).
73. Kozer E, Nikfar S, Costei A, Boskovic R, Nulman I, Koren G. Association of aspirin consumption during first trimester of pregnancy with congenital anomalies: a meta-analysis. Am. J. Obstet. Gynecol. 187(6), 1623-1630 (2002).
74. Rotchell YE, Cruicksank JK, Gay MP. Barbados low dose aspirin study in pregnancy (BLASP). A randomized trial for prevention of preeclampsia and its complications. Br. J. Obstet. Gynaecol. 105(3), 286-292 (1998).
75. Coomarasamy A, Honest H, Papioannou S, Gee H, Khan KS. Aspirin for prevention of preeclampsia in women with historical risk factors: a systematic review. Obstet. Gynecol. 101, 1319-1332 (2003).
76. Wilson AM, Boyle AJ, Fox P. Management of ischaemic heart disease in women of childbearing age. Intern. Med. J. 34, 694-697 (2004).
77. Al-Aqueedi RF, Al-Nabti AD. Drugeluting stent implantation for acute myocardial infarction during pregnancy with use of glycoprotein IIb/IIIa inhibitor, aspirin and clopidogrel. J. Invasive Cardiol. 20(5), E146-E149 (2008).
78. Chow T, Galvin J, McGovern B. Antiarrhythmic drug therapy in pregnancy and lactation. Am. J. Cardiol. 82, I58-I62 (1998).
79. Reimold SC, Rutherford JD. Valvular heart disease in pregnancy. N. Engl. J. Med. 349, 52-59 (2003).
80. Adamson DL, Nelson-Piercy C. Managing palpitations and arrhythmias during pregnancy. Heart 93, 1630-1636 (2007). • Excellent summary of antiarrhythmic drug use in pregnancy.
81. Motherisk www.motherisk.org
82. Otis Pregnancy www.otispregnancy.org
83. TERIS http://depts.washington.edu/terisweb/teris/
84. Reprotox www.reprotox.org
85. Developmental and Reproductive Toxicology, Toxnet www.toxnet.nlm.nih.gov